Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5106-11. doi: 10.1073/pnas.1001064107. Epub 2010 Mar 1.

2.

Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.

Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K.

Nature. 2014 Sep 25;513(7519):512-6. doi: 10.1038/nature13495. Epub 2014 Jul 20.

3.

Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.

Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J.

J Biol Chem. 2013 Jun 21;288(25):18219-27. doi: 10.1074/jbc.M113.475376. Epub 2013 May 14. Erratum in: J Biol Chem. 2013 Dec 27;288(52):37368.

4.

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Staffas A, Karlsson C, Persson M, Palmqvist L, Bergo MO.

Leukemia. 2015 May;29(5):1032-40. doi: 10.1038/leu.2014.315. Epub 2014 Nov 5.

PMID:
25371176
5.

New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.

Hales EC, Taub JW, Matherly LH.

Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Review.

PMID:
24140475
6.

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K.

Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16.

PMID:
28215705
7.

Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.

Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP.

Blood. 2010 Feb 11;115(6):1175-84. doi: 10.1182/blood-2009-04-214718. Epub 2009 Dec 11.

8.

The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.

Mendes RD, Canté-Barrett K, Pieters R, Meijerink JP.

Haematologica. 2016 Sep;101(9):1010-7. doi: 10.3324/haematol.2016.146381. Review.

9.

In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J.

Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.

10.

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.

Durinck K, Wallaert A, Van de Walle I, Van Loocke W, Volders PJ, Vanhauwaert S, Geerdens E, Benoit Y, Van Roy N, Poppe B, Soulier J, Cools J, Mestdagh P, Vandesompele J, Rondou P, Van Vlierberghe P, Taghon T, Speleman F.

Haematologica. 2014 Dec;99(12):1808-16. doi: 10.3324/haematol.2014.115683. Epub 2014 Oct 24.

11.

Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.

Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA.

Blood. 2011 Aug 11;118(6):1579-90. doi: 10.1182/blood-2010-08-300343. Epub 2011 Jun 13.

12.

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.

Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA.

Blood. 2009 Jun 11;113(24):6172-81. doi: 10.1182/blood-2008-02-136762. Epub 2009 Feb 26.

13.

Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.

Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, Krishnamoorthy V, Bhasin M, Capobianco AJ, Kelliher MA.

Mol Cell Biol. 2006 Nov;26(21):8022-31. Epub 2006 Sep 5.

14.

Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia.

Witkowski MT, Cimmino L, Hu Y, Trimarchi T, Tagoh H, McKenzie MD, Best SA, Tuohey L, Willson TA, Nutt SL, Busslinger M, Aifantis I, Smyth GK, Dickins RA.

Leukemia. 2015 Jun;29(6):1301-11. doi: 10.1038/leu.2015.27. Epub 2015 Feb 6.

15.

Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J, Strack PR, Winter CG, Winter SS, Larson RS, von Boehmer H, Look AT.

Blood. 2010 Mar 4;115(9):1735-45. doi: 10.1182/blood-2009-07-235143. Epub 2009 Dec 9.

16.

Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.

Palomero T, Ferrando A.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S205-10. doi: 10.3816/CLM.2009.s.013. Review.

17.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

18.

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG.

Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24.

19.

Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis.

Gómez-del Arco P, Kashiwagi M, Jackson AF, Naito T, Zhang J, Liu F, Kee B, Vooijs M, Radtke F, Redondo JM, Georgopoulos K.

Immunity. 2010 Nov 24;33(5):685-98. doi: 10.1016/j.immuni.2010.11.008.

20.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS.

Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.

Supplemental Content

Support Center